APRI might hold a future...

Discussion in 'Stocks' started by MarketRipper, Feb 25, 2018.

  1. Would like to hear some feedback here... APRI had the Vitaros ED treatment rejected once again by FDA last week. The rejection didn't sound terminal, and the drug is approved in about relevant 10 European countries, so not totally controversial. My take is that the method of administration is quite different from is out there, and seems no avoid taking a systemic delivery for what could be treated locally. If/when approved, this could explode back to the high $20+, form the current $1.03 is now...

    "The company said Vitaros is now approved in the Netherlands, Germany, France, Italy, and the U.K., among other countries, for the treatment of erectile dysfunction."

    Whats your take on this?